Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment

  • Veru Inc (NASDAQ:VERU) has submitted an emergency use authorization (EUA) for sabizabulin application to FDA for COVID-19 treatment.
  • The application covers moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS).
  • The EUA submission is based on the positive results from the Phase 3 COVID-19 clinical trial evaluating the efficacy and safety of sabizabulin in approximately 204 hospitalized COVID-19 patients at high risk for ARDS and death. 
  • Related: Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients.
  • "COVID-19 new cases and hospitalizations are on the rise again with a summer and fall-winter peaks expected," said Mitchell Steiner, Chairman, President, & CEO.
  • Veru is in Discussions with other regulatory agencies globally regarding emergency use authorization for sabizabulin, including the European Medicines Agency.
  • The company prepares for the U.S. Commercial Launch if EUA is granted.
  • Price Action: VERU shares are up 14.70% at $15.57 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.